Drugmaker Pfizer starts low with 2023 earnings forecast

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 63%

Österreich Nachrichten Nachrichten

Österreich Neuesten Nachrichten,Österreich Schlagzeilen

Pfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was anticipated by analysts, but the degree of the expected fall was not.

FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer reports their earnings Tuesday, Jan. 31, 2023.

Pfizer expects revenue from both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was anticipated by analysts as the drugmaker moves from supplying governments through big contracts to selling both products on the commercial market. Commercial sales of the vaccine and treatment are expected to start later this year in the U.S. While revenue from both will fall in 2023, analysts still expect the vaccine and treatment to each contribute billions of dollars in annual sales for the next several years.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 246. in AT
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen